This Medudy course is a conference report for physicians on the topic “ASCO 2026 – Updates on Prostate Cancer.”
Prof. Dr. Axel S. Merseburger, Director of the Department of Urology at the Lübeck Campus
of the University Medical Center Schleswig-Holstein, will summarize the important study highlights of the congress for you.
The presentation will cover the results of the Phase III PROTEUS study, which evaluated the efficacy and safety of apalutamide plus ADT before and after radical prostatectomy in patients with localized high-risk prostate cancer or locally advanced prostate cancer, as well as the results from the Phase IIITALAPRO-3 study, which investigated the combination of talazoparib plus enzalutamide in patients with metastatic hormone-sensitive prostate cancer.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
By the end of this conference report, you will know:
- Some of the highlights of ASCO 2026
- The most important takeaways from the studies presented
- The expert's conclusion on the studies presented
